Search - tctmd.com

Displaying 41 - 60 of 80

Sort: Relevancy | Date

Presentation TVT 2017

The Evolut R TAVR System: A Cool Case, New Technology (Including 34mm), and Clinical Program Updates

Presenter: Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

TAVR for Pure Aortic Insufficiency (AI) With Prior Ascending Aortic Hemi-shield Repair : Unique Role for EVOLUT-R

Presenter: Albert Markus Kasel, Thomas Walther, Soundos Moualla, MD

June 15, 2017

Presentation TVT 2017

Expert Commentary: Evolut R in Degenerative Surgical Aortic Bioprostheses (VIVA Registry)

Presenter: Ran Kornowski

June 15, 2017

Presentation TVT 2017

A Surgeon/Interventionalists Perspectives of Transcatheter Mitral and Tricuspid Valve Therapies Evolution, Impact, and Future Expectations

Presenter: Mark Reisman, Gregg W. Stone, Francesco Maisano

June 15, 2017

Presentation TVT 2017

Impact of Valvular Heart Disease on the Global Burden of Heart Failure: Can Transcatheter Therapies Make a Difference?

Presenter: Mark Reisman, Gregg W. Stone, Clyde W. Yancy

June 15, 2017

Presentation TVT 2017

TAVR in Perspective Evolution, Impact, and Future Expectations

Presenter: Mark Reisman, Gregg W. Stone, Martin B. Leon

June 15, 2017

Presentation TVT 2017

Are the Guidelines Keeping Pace With Evidence Generation and Clinical Practice? Responding to a Decade of Rapidly Changing Transcatheter Valve Therapies

Presenter: Mark Reisman, Gregg W. Stone, Robert O. Bonow

June 15, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Industry News

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

May 18, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Industry News

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

May 15, 2017

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

L.A. McKeown

May 15, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Daily News

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

L.A. McKeown

April 12, 2017

Presentation Fellows 2017

The Evolution of Drug-Eluting Stents

Presenter: Ajay J. Kirtane

April 07, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

Advertisement

The Evolut R TAVR System: A Cool Case, New Technology (Including 34mm), and Clinical Program Updates

TAVR for Pure Aortic Insufficiency (AI) With Prior Ascending Aortic Hemi-shield Repair : Unique Role for EVOLUT-R

Expert Commentary: Evolut R in Degenerative Surgical Aortic Bioprostheses (VIVA Registry)

A Surgeon/Interventionalists Perspectives of Transcatheter Mitral and Tricuspid Valve Therapies Evolution, Impact, and Future Expectations

Impact of Valvular Heart Disease on the Global Burden of Heart Failure: Can Transcatheter Therapies Make a Difference?

TAVR in Perspective Evolution, Impact, and Future Expectations

Are the Guidelines Keeping Pace With Evidence Generation and Clinical Practice? Responding to a Decade of Rapidly Changing Transcatheter Valve Therapies

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

More Early Stroke With SAVR Than TAVR in SURTAVI

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

Bioresorbable Scaffolds: Where Do We Go From Here?

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

The Evolution of Drug-Eluting Stents

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content